CA
NZ
UK
AU
IND
US
NIQ Global Intelligence plc filed a Form 8-K on November 12, 2026, disclosing both its financial results for the nine months ended September 30, 2026, and a newly approved share repurchase program of up to $150.0 million.
BK Technologies Corporation filed a Form 8-K on November 12, 2026, disclosing that its Board of Directors authorized a $5.0 million increase to its existing share repurchase program on November 11, 2026, bringing the total authorized amount to $10.0 million.
Alkermes Public Limited Company filed a Form 8-K on November 12, 2026, disclosing that two of its wholly-owned indirect subsidiaries entered into a confidential settlement and license agreement with Teva Pharmaceuticals, Inc. on November 6, 2026, resolving a patent infringement lawsuit over all dosage …
StepStone Group Inc. filed a Form 8-K on November 12, 2026, disclosing that Co-Chief Operating Officer Jose A. Fernandez stepped down from his executive officer role effective November 11, 2026, and that Co-COO Jason P. Ment's title and responsibilities were simultaneously restructured.
Pelthos Therapeutics Inc. filed a Post-Effective Amendment No. 1 to two previously filed Form S-8 registration statements on November 12, 2026, to register rollover shares under its newly approved 2026 Equity Incentive Plan.
Pelthos Therapeutics Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 12, 2026, to register 500,000 shares of common stock issuable under its newly adopted 2026 Equity Incentive Plan.
Absci Corporation filed a Form 8-K on November 12, 2026, announcing its financial results for the third quarter ended September 30, 2026, and releasing a corporate presentation with internal pipeline program updates.
Artisan Partners Asset Management Inc. and affiliated entities filed Amendment No. 7 to Schedule 13G with the SEC on November 12, 2026, reporting beneficial ownership of approximately 3.4% of Twist Bioscience Corporation common stock as of September 30, 2026.
Vor Biopharma Inc. filed a Current Report on Form 8-K on November 12, 2026, disclosing that on November 11, 2026, the company entered into an amended and restated license agreement with RemeGen Co., Ltd. that expands the existing telitacicept license to include a second …
Twist Bioscience Corporation filed a Form 8-K on November 12, 2026, announcing the release of its financial results for the quarter and fiscal year ended September 30, 2026.
Please wait processing your request...